Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms

The cell division cycle 25 (CDC25) phosphatases include CDC25A, CDC25B and CDC25C. These three molecules are important regulators of several steps in the cell cycle, including the activation of various cyclin-dependent kinases (CDKs). CDC25s seem to have a role in the development of several human malignancies, including acute myeloid leukemia (AML); and CDC25 inhibition is therefore considered as a possible anticancer strategy. Firstly, upregulation of CDC25A can enhance cell proliferation and the expression seems to be controlled through PI3K-Akt-mTOR signaling, a pathway possibly mediating chemoresistance in human AML. Loss of CDC25A is also important for the cell cycle arrest caused by differentiation induction of malignant hematopoietic cells. Secondly, high CDC25B expression is associated with resistance against the antiproliferative effect of PI3K-Akt-mTOR inhibitors in primary human AML cells, and inhibition of this isoform seems to reduce AML cell line proliferation through effects on NFκB and p300. Finally, CDC25C seems important for the phenotype of AML cells at least for a subset of patients. Many of the identified CDC25 inhibitors show cross-reactivity among the three CDC25 isoforms. Thus, by using such cross-reactive inhibitors it may become possible to inhibit several molecular events in the regulation of cell cycle progression and even cytoplasmic signaling, including activation of several CDKs, through the use of a single drug. Such combined strategies will probably be an advantage in human cancer treatment.

[1]  K. Döhner,et al.  Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Melachrinou,et al.  Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival. , 2007, Pathology, research and practice.

[3]  Hwangseo Park,et al.  Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[4]  J. V. van Deursen,et al.  Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation , 2011, The Journal of cell biology.

[5]  H. Niida,et al.  DNA damage checkpoints in mammals. , 2006, Mutagenesis.

[6]  Hyunseung Lee,et al.  A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. , 2013, Cancer letters.

[7]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[8]  B. Gjertsen,et al.  Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. , 2010, European cytokine network.

[9]  A. Kumagai,et al.  Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. , 2000, Molecular cell.

[10]  J. Ludlow Hypophosphorylation of pRB and repression of cyclin D3 and cdc25A during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells. , 1999, Leukemia research.

[11]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[12]  Peter Wipf,et al.  Redox Regulation of Cdc25B by Cell-Active Quinolinediones , 2005, Molecular Pharmacology.

[13]  T. Owa,et al.  Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. , 1999, Journal of medicinal chemistry.

[14]  D. Tenen,et al.  Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. , 2012, Journal of Clinical Investigation.

[15]  R. Medema,et al.  Polo-like kinase-1 is a target of the DNA damage checkpoint , 2000, Nature Cell Biology.

[16]  J. Yates,et al.  CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. , 2009, Cancer research.

[17]  Ø. Bruserud,et al.  Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia‐associated antigen associated with autoantibody response in a subset of patients , 2007, European journal of haematology.

[18]  Shengjun Ren,et al.  Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit , 2004, Cell.

[19]  Daniel G Tenen,et al.  Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. , 2010, Blood.

[20]  Daigo Inoue,et al.  Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism , 2004, The EMBO journal.

[21]  Satoki Nakamura,et al.  The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. , 2010, Carcinogenesis.

[22]  Jun-qing Du,et al.  LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation , 2009, Acta Pharmacologica Sinica.

[23]  M. Tanimoto,et al.  Overexpression of cyclin E in acute myelogenous leukemia. , 1997, Blood.

[24]  G. Biamonti,et al.  The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway. , 2006, Cancer research.

[25]  B. Ducommun,et al.  Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression , 2006, Molecular Cancer Therapeutics.

[26]  S. Reed,et al.  Different roles for cyclins D1 and E in regulation of the G1-to-S transition , 1995, Molecular and cellular biology.

[27]  S. Knappskog,et al.  Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia , 2012, Leukemia.

[28]  B. Villoutreix,et al.  Development of Novel Thiazolopyrimidines as CDC25B Phosphatase Inhibitors , 2009, ChemMedChem.

[29]  M. Berger,et al.  Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. , 2005, Cancer research.

[30]  R. Stam,et al.  MLL Fusion Driven Activation of CDK6 Potentiates Proliferation in MLL-rearranged Infant ALL , 2012 .

[31]  N. Hay,et al.  Akt Activation Emulates Chk1 Inhibition and Bcl2 Overexpression and Abrogates G2 Cell Cycle Checkpoint by Inhibiting BRCA1 Foci* , 2010, The Journal of Biological Chemistry.

[32]  Ø. Bruserud,et al.  Antileukaemic effect of PI3K‐mTOR inhibitors in acute myeloid leukaemia‐gene expression profiles reveal CDC25B expression as determinate of pharmacological effect , 2014, British journal of haematology.

[33]  B. Ducommun,et al.  Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. , 2006, Cancer Research.

[34]  Ø. Bruserud,et al.  Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases , 2010, Hematology.

[35]  T. Hervig,et al.  Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia , 2013, Transfusion medicine.

[36]  Ø. Bruserud,et al.  Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia? , 2012, Expert opinion on investigational drugs.

[37]  G. Mufti,et al.  Analysis of CHK2 in patients with myelodysplastic syndromes. , 2002, Leukemia research.

[38]  S. Manenti,et al.  Upregulation of the CDC25A phosphatase downstream of the NPM/ALK oncogene participates in anaplastic large cell lymphoma enhanced proliferation , 2009, Cell cycle.

[39]  E. Novellino,et al.  CDC25 phosphatase inhibitors: an update. , 2012, Mini reviews in medicinal chemistry.

[40]  T. Owa,et al.  Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment , 2012, Cancer Chemotherapy and Pharmacology.

[41]  B. Ducommun,et al.  Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. , 2009, Cancer research.

[42]  A. Lindqvist,et al.  Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1–Cdk1 at the centrosome , 2005, The Journal of cell biology.

[43]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[44]  D. Inzé,et al.  What if higher plants lack a CDC25 phosphatase? , 2006, Trends in plant science.

[45]  H. Piwnica-Worms,et al.  Absence of Apparent Phenotype in Mice Lacking Cdc25C Protein Phosphatase , 2001, Molecular and Cellular Biology.

[46]  M. Grusch,et al.  In vitro anti-inflammatory and anticancer activities of extracts of Acalypha alopecuroidea (Euphorbiaceae). , 2009, International journal of oncology.

[47]  S. Bohlander,et al.  Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations , 2006, The Journal of experimental medicine.

[48]  Bernard Ducommun,et al.  Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases , 2005, Molecular Cancer Therapeutics.

[49]  B. Gabrielli,et al.  Hyperphosphorylation of the N-terminal Domain of Cdc25 Regulates Activity toward Cyclin B1/Cdc2 But Not Cyclin A/Cdk2* , 1997, The Journal of Biological Chemistry.

[50]  J. Byrd,et al.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide , 2009, Proceedings of the National Academy of Sciences.

[51]  L. Tessarollo,et al.  Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation , 2002, Nature Genetics.

[52]  P. Vaglio,et al.  Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. , 2003, Molecular biology of the cell.

[53]  B. Monsarrat,et al.  CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage , 2006, Journal of Cell Science.

[54]  Ettore Novellino,et al.  Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening. , 2012, Journal of medicinal chemistry.

[55]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[56]  J. Rudolph,et al.  Cdc25 phosphatases and cancer. , 2004, Chemistry & biology.

[57]  Donald Bashford,et al.  Stabilization of Charges and Protonation States in the Active Site of the Protein Tyrosine Phosphatases: A Computational Study† , 2000 .

[58]  Ø. Bruserud,et al.  Review: genetic models of acute myeloid leukaemia , 2008, Oncogene.

[59]  M. Yaffe,et al.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. , 2009, Current opinion in cell biology.

[60]  Todd D. Westergard,et al.  Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint , 2010, Nature.

[61]  M. Levis,et al.  Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. , 2004, Blood.

[62]  M. Cazales,et al.  Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly , 2007, Molecular Cancer Therapeutics.

[63]  R. Poon,et al.  How protein kinases co-ordinate mitosis in animal cells. , 2011, The Biochemical journal.

[64]  T. Szekeres,et al.  In vitro anti-leukemic activity of the ethno-pharmacological plant Scutellaria orientalis ssp. carica endemic to western Turkey. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[65]  M. Lübbert,et al.  CXCR4 is a prognostic marker in acute myelogenous leukemia. , 2007, Blood.

[66]  M. Sanders,et al.  The evolving molecular genetic landscape in acute myeloid leukaemia. , 2013, Current opinion in hematology.

[67]  W M Miller,et al.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. , 2001, Biophysical journal.

[68]  B. Gjertsen,et al.  Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. , 2006, Current pharmaceutical biotechnology.

[69]  Ø. Bruserud,et al.  Animal models of acute myelogenous leukaemia – development, application and future perspectives , 2005, Leukemia.

[70]  C. Frazer,et al.  Phosphorylation Mediated Regulation of Cdc25 Activity, Localization and Stability , 2012 .

[71]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[72]  M. Takagi,et al.  Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. , 2003, Blood.

[73]  Alessandra Montecucco,et al.  Cellular response to etoposide treatment. , 2007, Cancer letters.

[74]  Katsunori Tanaka Multiple Functions of the S-Phase Checkpoint Mediator , 2010, Bioscience, biotechnology, and biochemistry.

[75]  Ming Yan,et al.  A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. , 2007, Blood.

[76]  L. Busino,et al.  Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis , 2004, Oncogene.

[77]  L. Larocca,et al.  Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia , 2006, British Journal of Cancer.

[78]  C. Wilcox,et al.  Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. , 2003, Biochemistry.

[79]  A. Floridi,et al.  The retinoblastoma gene product in acute myeloid leukemia: a possible involvement in promyelocytic leukemia. , 1995, Cancer research.

[80]  Ø. Bruserud,et al.  Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients , 2013, Cell proliferation.

[81]  R. Wäsch,et al.  Cell cycle control in acute myeloid leukemia. , 2012, American journal of cancer research.

[82]  Arnaud M. Vigneron,et al.  The STAT3 Transcription Factor Is a Target for the Myc and Riboblastoma Proteins on the Cdc25A Promoter* , 2005, Journal of Biological Chemistry.

[83]  P. Wipf,et al.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. , 2009, Assay and drug development technologies.

[84]  M. Odero,et al.  PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect , 2011, Leukemia.

[85]  K. Noguchi,et al.  Physical and Functional Interactions between Pim-1 Kinase and Cdc25A Phosphatase , 1999, The Journal of Biological Chemistry.

[86]  E. Novellino,et al.  CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy. , 2009, Current medicinal chemistry.

[87]  A. Lindqvist,et al.  Cdc25A localisation and shuttling: characterisation of sequences mediating nuclear export and import. , 2005, Experimental cell research.

[88]  R. Medema,et al.  Aurora-A and hBora join the game of Polo. , 2009, Cancer research.

[89]  T. Naoe,et al.  Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia , 2000, Leukemia.

[90]  P. Hieter,et al.  PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. , 1998, Molecular cell.

[91]  Ø. Bruserud,et al.  Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. , 2009, Critical reviews in oncogenesis.

[92]  Kumar Somyajit,et al.  RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer , 2010, Carcinogenesis.

[93]  Mitsuhiro Yanagida,et al.  Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and BubR1. , 2007, Developmental cell.

[94]  Y. Liou,et al.  Phosphorylation of Mixed Lineage Leukemia 5 by Cdc2 Affects Its Cellular Distribution and Is Required for Mitotic Entry* , 2010, The Journal of Biological Chemistry.

[95]  Jiri Bartek,et al.  Regulation of G2/M events by Cdc25A through phosphorylation‐dependent modulation of its stability , 2002, The EMBO journal.

[96]  Wei Zhang,et al.  Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy , 2009, Molecular Cancer.

[97]  M. Lübbert,et al.  Cyclin A1 expression in leukemia and normal hematopoietic cells. , 1999, Blood.

[98]  H. Lane,et al.  On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. , 1997, Biochemical and biophysical research communications.

[99]  Ettore Novellino,et al.  Modeling of Cdc25B Dual Specifity Protein Phosphatase Inhibitors: Docking of Ligands and Enzymatic Inhibition Mechanism , 2006, ChemMedChem.

[100]  G. Landberg,et al.  Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells , 2004, Oncogene.

[101]  Anthony J. Muslin,et al.  14-3-3 proteins: regulation of subcellular localization by molecular interference. , 2000, Cellular signalling.

[102]  Yasutaka Tanaka,et al.  Transcriptional Repression of Cdc25B by IER5 Inhibits the Proliferation of Leukemic Progenitor Cells through NF-YB and p300 in Acute Myeloid Leukemia , 2011, PloS one.

[103]  J. Lazo,et al.  Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione. , 2002, The Journal of biological chemistry.

[104]  E. Novellino,et al.  Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review , 2010, Expert opinion on therapeutic patents.

[105]  J. Rudolph Cdc25 phosphatases: structure, specificity, and mechanism. , 2007, Biochemistry.

[106]  E. Fauman,et al.  Crystal Structure of the Catalytic Domain of the Human Cell Cycle Control Phosphatase, Cdc25A , 1998, Cell.

[107]  Jenny Ekberg,et al.  Post-translational modification of cyclin A1 is associated with staurosporine and TNFα induced apoptosis in leukemic cells , 2008, Molecular and Cellular Biochemistry.

[108]  M. McDevitt,et al.  Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias , 2012, Clinical Cancer Research.

[109]  P. Corn,et al.  The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan , 2014, Leukemia & lymphoma.

[110]  J. Slingerland,et al.  Stem cell factor inhibits erythroid differentiation by modulating the activity of G1-cyclin-dependent kinase complexes: a role for p27 in erythroid differentiation coupled G1 arrest. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[111]  Stefan Fröhling,et al.  Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. , 2013, Blood.

[112]  F. Mandelli,et al.  High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias , 2003, Annals of Hematology.

[113]  K D Watenpaugh,et al.  Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. , 1999, Journal of molecular biology.

[114]  R. Mantovani,et al.  NF-Y and the transcriptional activation of CCAAT promoters , 2012, Critical reviews in biochemistry and molecular biology.

[115]  Ø. Bruserud,et al.  Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia , 2014, Molecular Cancer.

[116]  T. Pandita,et al.  Lack of PTEN sequesters CHK1 and initiates genetic instability. , 2005, Cancer cell.

[117]  N. Hayward,et al.  Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. , 1996, Journal of cell science.

[118]  S. Keyse,et al.  Amino acid sequence similarity between CL100, a dual-specificity MAP kinase phosphatase and cdc25. , 1993, TIBS -Trends in Biochemical Sciences. Regular ed.

[119]  J. Lazo,et al.  Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione* , 2002, The Journal of Biological Chemistry.

[120]  F. Ajchenbaum‐Cymbalista,et al.  Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure , 2001, Leukemia.

[121]  I. Grummt,et al.  Human Cdc14B Promotes Progression through Mitosis by Dephosphorylating Cdc25 and Regulating Cdk1/Cyclin B Activity , 2011, PloS one.

[122]  D. Beach,et al.  Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins , 1991, Cell.

[123]  H. Piwnica-Worms,et al.  Normal Cell Cycle and Checkpoint Responses in Mice and Cells Lacking Cdc25B and Cdc25C Protein Phosphatases , 2005, Molecular and Cellular Biology.

[124]  Yi Zang,et al.  Discovery and characterization of a novel inhibitor of CDC25B, LGH00045 , 2008, Acta Pharmacologica Sinica.

[125]  Christian Bailly,et al.  Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. , 2009, Blood.

[126]  J. Rudolph Targeting the Neighbor's Pool , 2004, Molecular Pharmacology.

[127]  J. Rudolph,et al.  Remote hot spots mediate protein substrate recognition for the Cdc25 phosphatase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[128]  D. Gillespie,et al.  Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2 , 2010, The Journal of cell biology.

[129]  B. Novák,et al.  Switches and latches: a biochemical tug-of-war between the kinases and phosphatases that control mitosis , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[130]  A. Martelli,et al.  Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia. , 2005, Advances in enzyme regulation.

[131]  Z. Darżynkiewicz,et al.  DNA damage response as a biomarker in treatment of leukemias , 2009, Cell cycle.

[132]  R. Stam,et al.  MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL , 2014, Cell cycle.

[133]  P. Salaun,et al.  Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards. , 2008, Advances in experimental medicine and biology.

[134]  Cun-Yu Wang,et al.  Regulation of the G2–M cell cycle progression by the ERK5–NFκB signaling pathway , 2007, The Journal of cell biology.

[135]  Ø. Bruserud,et al.  Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents , 2013, Clinical Epigenetics.

[136]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[137]  N. Mailand,et al.  Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase , 2004, Nature Cell Biology.

[138]  Peter Wipf,et al.  Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. , 2002, Molecular pharmacology.

[139]  M. Pagano,et al.  Dual mode of degradation of Cdc25 A phosphatase , 2002, The EMBO journal.

[140]  B. Ducommun,et al.  IRC‐083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells , 2009, International journal of cancer.

[141]  J. Yates,et al.  Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry , 2008, Science.

[142]  J. A. Tercero,et al.  The S‐phase checkpoint: targeting the replication fork , 2009, Biology of the cell.

[143]  H. Kindler,et al.  A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma , 2007 .

[144]  M. Teixeira,et al.  SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23) , 2006, Oncogene.

[145]  Jianxiang Wang,et al.  RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia. , 2011, Leukemia research.

[146]  J. Slingerland,et al.  Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression , 2003, Cell cycle.

[147]  B. Ducommun,et al.  G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress , 2008, Oncogene.

[148]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[149]  C. Supuran,et al.  Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. , 2004, Bioorganic & medicinal chemistry letters.

[150]  E. Karsenti,et al.  Activation of the phosphatase activity of human cdc25A by a cdk2‐cyclin E dependent phosphorylation at the G1/S transition. , 1994, The EMBO journal.

[151]  T. Shen,et al.  The role of Cdc25A in the regulation of cell proliferation and apoptosis. , 2012, Anti-cancer agents in medicinal chemistry.

[152]  R. Mesa,et al.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. , 2005, Blood.

[153]  E. Rego,et al.  High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. , 2011, Leukemia research.

[154]  Jan-Gowth Chang,et al.  Expression of hBUB1 in Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.

[155]  C. Readhead,et al.  Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. , 2001, Blood.

[156]  Ø. Bruserud,et al.  The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia , 2013, Clinical Epigenetics.

[157]  Bernard Ducommun,et al.  The when and wheres of CDC25 phosphatases. , 2006, Current opinion in cell biology.

[158]  W M Miller,et al.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. , 2001, Biophysical journal.

[159]  H. Piwnica-Worms,et al.  DNA Damage and Replication Checkpoints in Fission Yeast Require Nuclear Exclusion of the Cdc25 Phosphatase via 14-3-3 Binding , 1999, Molecular and Cellular Biology.

[160]  G. Nolan,et al.  Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. , 2007, Blood.

[161]  Ø. Bruserud,et al.  Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels , 2008, Leukemia.

[162]  Qi Zhu,et al.  Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia , 2011, International journal of cancer.

[163]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[164]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[165]  I. Hoffmann,et al.  Ectopic Expression of Cdc25A Accelerates the G1/S Transition and Leads to Premature Activation of Cyclin E- and Cyclin A-Dependent Kinases , 1999, Molecular and Cellular Biology.

[166]  M. Heinrich,et al.  An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  Ming Yan,et al.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. , 2007, Blood.

[168]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[169]  D. Steensma,et al.  Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes , 2008, Leukemia & lymphoma.